Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Development

Background:

• The introduction of molecular target agents has revolutionized cancer treatment since the late 1990s.
• A significant 'drug lag' has historically affected Japan's access to globally developed cancer therapies.
• Recent trends show increased Japanese participation in international clinical trials, reducing this lag.

Purpose of the Study:

• To review the progress and impact of molecular target agents in treating gastrointestinal malignancies in Japan.
• To highlight the evolving role of Japanese institutions in global drug development and clinical trials.
• To discuss the future outlook for molecular target agent utilization in Japan.

Main Methods:

• Review of recent clinical trial participation and drug approvals for molecular target agents in Japan.
• Analysis of treatment outcomes for specific gastrointestinal cancers (colorectal, gastric, pancreatic, liver, esophageal).
• Examination of the role of investigator-initiated trials and global collaboration.

Main Results:

• Molecular target agents like bevacizumab and cetuximab have improved outcomes for colorectal cancer in Japan.
• Japanese institutions are actively contributing to global trials for gastric cancer agents (trastuzumab, bevacizumab) and leading early development.
• Progress in pancreatic, liver, and esophageal cancer treatments with molecular target agents varies, emphasizing the need for global collaboration and investigator-initiated trials.

Conclusions:

• Molecular target agents represent significant progress in treating gastrointestinal malignancies.
• Increased participation of Japanese institutions in global trials is crucial for accelerating drug availability and improving patient outcomes.
• Further research is needed in Japan to optimize the use of these agents in daily clinical practice.